TGFβ signaling is a major driver of EMT in NSCLC cells, a cellular transformation that facilitates drug resistance to cytotoxic agents such as platin based as well as targeted therapies and immunotherapy [35,36]. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.